Altered platelet monoamine oxidase-B activity in idiopathic Parkinson's disease.
A case-control study was undertaken to investigate the status of platelet monoamine oxidase-B (MAO-B) activity in Indian cases of idiopathic Parkinson's disease. A significant increase in the activity of platelet MAO-B was observed in Parkinson's cases (n = 26) as compared to controls (n = 26). No significant change in the activity of the enzyme was observed while the data was analysed with respect to age, sex and duration of disease. A trend of decrease in platelet MAO-B activity was observed in Parkinson's cases with respect to stage although the change was not significant. No correlation in platelet MAO-B activity was observed with respect to age and sex in the control subjects. Parkinson's cases treated with L-DOPA and MAO-B inhibitor exhibited decreased platelet MAO-B activity as compared to drug naive cases and those treated with L-DOPA alone. Interestingly, Parkinson's cases treated with L-DOPA and amantadine also had lower platelet MAO-B activity as compared to drug naive cases and those treated with L-DOPA alone. Activity of platelet MAO-B in Parkinson's patients was increased in naive cases and those treated with L-DOPA alone or in combination with other drugs compared to controls. The results of the present study indicate that phenotypic activity of platelet MAO-B is high in Indian Parkinson's cases. Further, action mechanism of drugs used in the treatment of Parkinson's disease could be understood by assay of platelet MAO-B activity. It is an interesting observation and may be looked further in large number of cases.
Husain
Maroof
M
Developmental Toxicology Division, Indian Institute of Toxicology Research, (Formerly Industrial Toxicology Research Centre), MG Marg, P.O. Box 80, Lucknow 226001, India.
Shukla
Rakesh
R
Dikshit
Madhu
M
Maheshwari
Pradeep K
PK
Nag
Devika
D
Srimal
Rikhab C
RC
Seth
Prahlad K
PK
Khanna
Vinay K
VK
D000328:Adult; D000368:Aged; D000547:Amantadine / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001792:Blood Platelets / Q000201:enzymology*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007194:India; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D008995:Monoamine Oxidase / Q000097:blood*; D010300:Parkinson Disease / Q000097:blood* / Q000188:drug therapy / Q000201:enzymology*; D055815:Young Adult
D000978:Antiparkinson Agents; D007980:Levodopa; D000547:Amantadine; D008995:Monoamine Oxidase